All In Biotech

Drug Trial Radar · NCT05208281

A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II

Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC "GENERIUM", Russia) in Patients With Mucopolysaccharidosis Type II

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Nov 30, 2021

Primary completion

Dec 20, 2027

Study completion Mar 2028

Sponsor

Lead sponsor
AO GENERIUMIndustry
Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is phase 2/3 study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the investigational product GNR-055 in MPS II (Hunter syndrome) patients of different age groups.

Conditions

  • Mucopolysaccharidosis Type II
  • Metabolic Diseases

Interventions

  • GNR-055 1.0-2.0-3.0 mg/kgDrug

    Weekly IV infusion (lyophilized powder) 1.0-2.0-3.0 mg/kg

  • GNR-055 2.0 mg/kgDrug

    Weekly IV infusion (lyophilized powder) 2.0 mg/kg

  • GNR-055 3.0 mg/kgDrug

    Weekly IV infusion (lyophilized powder) 3.0 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline to Week 56
  2. Urine GAG excretionTime frame: Baseline to Week 4, 8, 10, 26, and 52

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Federal State-Funded Healthcare Institution Central Clinical Hospital of the Russian Academy of Sciences (Research Institute of Pediatrics and Child Health Protection of the Central Clinical Hospital of the Russian Academy of Sciences)

    Moscow, Russia

  • Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University" of the Ministry of Health of the Russian Federation

    Saint Petersburg, Russia

  • V.I. Vernadsky Crimean Federal University

    Simferopol, Russia

  • State Budgetary Healthcare Institution Republican Medical Genetic Center

    Ufa, Russia

  • State Autonomous Healthcare Institution of the Sverdlovsk Region Regional Children's Clinical Hospital

    Yekaterinburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.